JOIN THE INNOVATION

EVis Bioscience is now live on Capital Cell, raising €700k at a €12M valuation.

We are developing a patented NanoVector platform that overcomes the key limitations of current RNA delivery systems — enabling safer, targeted, extrahepatic delivery for the next generation of gene therapies.

JOIN US

Be part of a breakthrough designed to unlock new treatments for currently untreatable genetic diseases.

TECHNOLOGY

Next-Generation RNA Delivery

Our patented NanoVector platform enables safer, targeted, extrahepatic delivery beyond current viral and non-viral systems.

MARKET

The global gene therapy market is expanding rapidly, creating strong demand for more precise and scalable delivery technologies.

IMPACT

Our approach opens new therapeutic opportunities for patients with genetic disorders lacking effective treatments today.

MOMENTUM

A scalable, low-toxicity platform already attracting scientific interest and moving toward market readiness. Ready for Commercialization by 2026

Invest in a Breakthrough RNA Delivery Platform

Support a patented technology designed to enable safer, targeted treatments for genetic diseases — and be part of our journey toward commercialization in 2026.

Overview

Valuation

Estimated return

% Offered

Estimated exit